Wedbush Says Buy Omeros (OMER) on Weakness from Mixed OMS103HP Phase 3 Results
Tweet Send to a FriendGet Alerts OMER Hot Sheet
Price: $5.18 +4.23%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade OMER Now!
Wedbush is telling clients to buy Omeros Corp. (NASDAQ: OMER) on weakness in light of mixed OMS103HP Phase 3 results which has pressured shares 7 percent in extended trading. The firm said the results still warrant continued development and OMS302 is still on track for NDA filing in the 1st-half of 2013.
"Although the primary endpoint of Knee Injury and Osteoarthritis Outcome Score (KOOS) Symptoms subscale trended positively, it failed to show statistical significance in this first of two planned Phase 3 trials testing OMS103HP treatment to control inflammation and pain during arthroscopic meniscectomy knee surgery. However, an important secondary endpoint of inflammatory pain did achieve statistical significance (visual analog score or VAS at day 1, p=0.0001) and was consistent with other inflammatory endpoints. The company plans to initiate a second Phase 3 trial in H1:13 using inflammatory pain as the primary endpoint."
The firm also notes Omeros is not a one-trick pony. "Recall that OMS103HP is Omeros second drug candidate and the lead, OMS302 for eye surgery, has already passed two Phase 3 trials and the company is on track for NDA filing in H1:13. Not only is OMS302 the company’s lead drug candidate but we project gross peak annual sales worldwide could reach over $600 million versus about $250 million for OMS103HP in meniscectomy. With two positive Phase 3 trials under their belt for OMS302 and a planned NDA filing in Q1 2013, we could see potential FDA approval in late 2013/early 2014. In addition, the company has multiple earlier stage candidates to reduce clinical risk."
The firm reiterated an Outperform rating and price target of $20.00.
For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.
Shares of Omeros Corp. closed at $5.84 yesterday, with a 52 week range of $3.95-$13.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"Although the primary endpoint of Knee Injury and Osteoarthritis Outcome Score (KOOS) Symptoms subscale trended positively, it failed to show statistical significance in this first of two planned Phase 3 trials testing OMS103HP treatment to control inflammation and pain during arthroscopic meniscectomy knee surgery. However, an important secondary endpoint of inflammatory pain did achieve statistical significance (visual analog score or VAS at day 1, p=0.0001) and was consistent with other inflammatory endpoints. The company plans to initiate a second Phase 3 trial in H1:13 using inflammatory pain as the primary endpoint."
The firm also notes Omeros is not a one-trick pony. "Recall that OMS103HP is Omeros second drug candidate and the lead, OMS302 for eye surgery, has already passed two Phase 3 trials and the company is on track for NDA filing in H1:13. Not only is OMS302 the company’s lead drug candidate but we project gross peak annual sales worldwide could reach over $600 million versus about $250 million for OMS103HP in meniscectomy. With two positive Phase 3 trials under their belt for OMS302 and a planned NDA filing in Q1 2013, we could see potential FDA approval in late 2013/early 2014. In addition, the company has multiple earlier stage candidates to reduce clinical risk."
The firm reiterated an Outperform rating and price target of $20.00.
For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.
Shares of Omeros Corp. closed at $5.84 yesterday, with a 52 week range of $3.95-$13.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: UBS Starts Insmed (INSM) at Buy
- Wells Fargo Cuts Comerica (CMA) and First Horizon National (FHN) to Underperform
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
